---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-23-000053"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2023-09-18T23:59:59+00:00"
generated_at: "2026-06-10T15:44:02.303560+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ligand merges Pelican unit into Primrose Bio, retains 49.9% stake and milestone rights

## Summary
- Subsidiary Pelican Technology merged into Primrose Bio; Ligand owns 49.9% of the combined company.
- Ligand retains all existing Pelican Expression Technology royalties (RYLAZE, VAXNEUVANCE, V116, Teriparatide, Pneumosil, MenFive).
- Ligand contributed $15M for rights to 50% of development milestones from two prior Primordial Genetics contracts.
- Starting 2025, Ligand receives 25% of PeliCRM197 sales revenue above $3M and 35% of PeliCRM197 licensing revenue.
- Combined platform pairs Pelican Expression Technology with Primordial Genetics' Function Generator for synthetic biology.

## SEC filing metadata
- accession: 0000886163-23-000053
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2023-09-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616323000053/0000886163-23-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616323000053/lgnd-20230918.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-23-000053
- JSON: https://secwatch.observer/filing/0000886163-23-000053.json
- Plain text: https://secwatch.observer/filing/0000886163-23-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.